Aktienyheder i dag

Seneste aktienyheder samlet ét sted. Læs aktienyheder gratis med fokus på de vigtigste bevægelser i markedet - også når der kommer aktienyheder Vestas og andre populære aktier.

SenesteReuters7. feb. 2026, 11.07

Weight-loss drugs to compete on biggest stage with Super Bowl ads

NEW YORK, Feb 7 (Reuters) - Companies looking to sell weight-loss drugs directly to consumers, including Novo Nordisk's Wegovy, will shell out millions of dollars for celebrity-filled ads during Sunday's Super Bowl with its promise of one of the year's largest global audiences. Novo’s 90-second spot has comedian and SNL stalwart Kenan Thompson announcing the new Wegovy pill to America and suggesting, ‌tongue-in-cheek along with music producer DJ Khaled, that people with obesity can benefit fro

Flere aktienyheder

Viser 20 seneste aktienyheder sorteret efter dato

Klik for at åbne nyheden i en ny fane

The Wall Street Journal·7. feb. 2026, 10.30

The Weight-Loss Price Wars Are Breaking Big Pharma’s Business Model

Two years ago, a GLP-1 prescription could cost an uninsured patient more than $1,000 a month. In the world of Big Pharma, this is unheard of. Typically, drug prices climb or plateau until generics arrive years later.

Simply Wall St.·7. feb. 2026, 07.05

Novo Nordisk Stock Pullback Tested By Wegovy Pills And New Rivals

Novo Nordisk (NYSE:NVO) has introduced an FDA approved oral version of its weight loss drug Wegovy, expanding its obesity treatment portfolio. Hims & Hers Health has launched a lower cost compounded alternative to Wegovy, increasing competitive pressure on Novo Nordisk. The FDA has raised safety and legality concerns around unauthorized compounded versions of GLP 1 weight loss drugs, bringing additional regulatory focus to the space. Novo Nordisk plans legal and regulatory action against...

Insider Monkey·7. feb. 2026, 05.56

Jim Cramer on Novo Nordisk: “It Seems Eli Lilly’s Eating Their Lunch”

Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer commented on. Cramer highlighted the company’s post-earnings decline, as he remarked: What went wrong at Novo Nordisk? Yesterday, the Danish drug maker behind Ozempic reported, and the stock plunged nearly 15% before sinking another 6% today. While the quarter was fine, the guidance, let’s […]

MarketBeat·7. feb. 2026, 03.08

Novo Nordisk A/S Q4 Earnings Call Highlights

Novo Nordisk A/S (NYSE:NVO) executives used the company’s fourth-quarter results presentation to walk investors through a year marked by weaker-than-expected growth, a sharp shift in the U.S. pricing environment, and an early—though still nascent—commercial signal from the newly launched Wegovy pill

Investing.com·6. feb. 2026, 22.45

FDA scrutiny rattles Hims & Hers stock

Investing.com -- Hims Hers Health Inc (NYSE:HIMS) shares plummeted 12.6% in after-hours trading Friday following a stark warning from federal regulators. The U.S. Food and Drug Administration announced its intent to take "decisive steps" against companies mass-marketing non-approved compounded GLP-1 drugs. The agency’s intervention specifically targets active pharmaceutical ingredients used in products that Hims & Hers and other compounding pharmacies market as alternatives to approved treatment

Barrons.com·6. feb. 2026, 22.13

TrumpRx Is Here. Most People Won’t Benefit.

The initiative will offer discounted cash prices on about 40 drugs from the following manufacturers: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.

Barrons.com·6. feb. 2026, 21.13

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers

Amazon shares tumble after the tech and online retailing giant forecasts $200 billion in capital expenditures for 2026.